Addex Therapeutics Ltd
ADXN
$7.10
-$0.2022-2.77%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -71.75% | -58.86% | -14.54% | 20.27% | 71.24% |
| Total Other Revenue | 280.56% | 141.03% | 120.45% | 62.03% | -48.82% |
| Total Revenue | -70.04% | -57.51% | -13.21% | 20.92% | 69.32% |
| Cost of Revenue | -26.61% | -49.89% | -74.80% | -81.08% | -86.60% |
| Gross Profit | -45.31% | 45.02% | 86.10% | 92.22% | 94.69% |
| SG&A Expenses | -7.29% | -26.82% | -35.08% | -52.84% | -44.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.48% | -39.10% | -61.28% | -71.63% | -68.33% |
| Operating Income | -6.08% | 34.28% | 66.76% | 78.11% | 76.40% |
| Income Before Tax | -33.45% | 28.17% | 65.79% | 77.06% | 75.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.45% | 28.17% | 65.79% | 77.06% | 75.59% |
| Earnings from Discontinued Operations | 294.79% | 339.36% | -229.07% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 146.34% | 133.19% | 30.00% | 46.13% | 46.02% |
| EBIT | -6.08% | 34.28% | 66.76% | 78.11% | 76.40% |
| EBITDA | -3.47% | 34.87% | 66.40% | 77.88% | 76.37% |
| EPS Basic | 128.28% | 113.80% | 61.52% | 69.45% | 68.23% |
| Normalized Basic EPS | 12.24% | 57.20% | 82.19% | 88.04% | 84.58% |
| EPS Diluted | 124.97% | 113.21% | 60.49% | 68.67% | 67.54% |
| Normalized Diluted EPS | 19.58% | 61.15% | 82.19% | 88.04% | 84.58% |
| Average Basic Shares Outstanding | 42.11% | 50.87% | 63.78% | 64.87% | 69.54% |
| Average Diluted Shares Outstanding | 68.13% | 80.12% | 63.78% | 64.87% | 69.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
